A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

NCT05941507 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: LCB84
DRUG: Anti-PD-1 monoclonal antibody

Sponsor

LigaChem Biosciences, Inc.

Collaborators

[object Object]